Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akihisa Mori

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
International Review of Neurobiology|September 2, 2014
International Review of Neurobiology. Adenosine receptors in neurology and psychiatry. PrefaceAkihisa Mori
International Review of Neurobiology|September 2, 2014
Mode of action of adenosine A2A receptor antagonists as symptomatic treatment for Parkinson's diseaseAkihisa Mori
Parkinsonism & Related Disorders|December 22, 2020
How do adenosine A<sub>2A</sub> receptors regulate motor function?Akihisa Mori
Neurology|December 10, 2003
Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonistsAkihisa Mori, Tomomi Shindou
Waste Management (New York, N.Y.)|March 5, 2015
Revisiting the extended producer responsibility program for metal packaging in South KoreaSoyoung Kim, Akihisa Mori
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|April 15, 2008
[Recent and potential drug candidates for treatment of Parkinson's disease]Tomoyuki Kanda, Akihisa Mori
International Review of Neurobiology|September 23, 2023
How and why the adenosine A<sub>2A</sub> receptor became a target for Parkinson's disease therapyPeter Jenner, Tomoyuki Kanda, Akihisa Mori
Parkinsonism & Related Disorders|December 22, 2020
Can adenosine A<sub>2A</sub> receptor antagonists be used to treat cognitive impairment, depression or excessive sleepiness in Parkinson's disease?Peter Jenner, Akihisa Mori, Tomoyuki Kanda
Expert Review of Neurotherapeutics|January 28, 2021
Istradefylline - a first generation adenosine A<sub>2A</sub> antagonist for the treatment of Parkinson's diseasePeter Jenner, Akihisa Mori, Stephen D Aradi, et al.
Pharmacology, Biochemistry, and Behavior|November 9, 2013
Antidepressant-like activity of the adenosine A(2A) receptor antagonist, istradefylline (KW-6002), in the forced swim test and the tail suspension test in rodentsKoji Yamada, Minoru Kobayashi, Akihisa Mori, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
International Review of Neurobiology|September 2, 2014
International Review of Neurobiology. Adenosine receptors in neurology and psychiatry. PrefaceAkihisa Mori
International Review of Neurobiology|September 2, 2014
Mode of action of adenosine A2A receptor antagonists as symptomatic treatment for Parkinson's diseaseAkihisa Mori
Parkinsonism & Related Disorders|December 22, 2020
How do adenosine A<sub>2A</sub> receptors regulate motor function?Akihisa Mori
Neurology|December 10, 2003
Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonistsAkihisa Mori, Tomomi Shindou
Waste Management (New York, N.Y.)|March 5, 2015
Revisiting the extended producer responsibility program for metal packaging in South KoreaSoyoung Kim, Akihisa Mori
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|April 15, 2008
[Recent and potential drug candidates for treatment of Parkinson's disease]Tomoyuki Kanda, Akihisa Mori
International Review of Neurobiology|September 23, 2023
How and why the adenosine A<sub>2A</sub> receptor became a target for Parkinson's disease therapyPeter Jenner, Tomoyuki Kanda, Akihisa Mori
Parkinsonism & Related Disorders|December 22, 2020
Can adenosine A<sub>2A</sub> receptor antagonists be used to treat cognitive impairment, depression or excessive sleepiness in Parkinson's disease?Peter Jenner, Akihisa Mori, Tomoyuki Kanda
Expert Review of Neurotherapeutics|January 28, 2021
Istradefylline - a first generation adenosine A<sub>2A</sub> antagonist for the treatment of Parkinson's diseasePeter Jenner, Akihisa Mori, Stephen D Aradi, et al.
Pharmacology, Biochemistry, and Behavior|November 9, 2013
Antidepressant-like activity of the adenosine A(2A) receptor antagonist, istradefylline (KW-6002), in the forced swim test and the tail suspension test in rodentsKoji Yamada, Minoru Kobayashi, Akihisa Mori, et al.
Pageof 4